Condition (MeSH)
Albinism, Oculocutaneous
ClinicalTrials.gov lists 18 trials for Albinism, Oculocutaneous or a narrower condition beneath it. National Human Genome Research Institute (NHGRI) has the most among industry and government lead sponsors, with 6.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
9 of the 18 trials are tagged with Albinism, Oculocutaneous itself; the rest are tagged with a narrower condition beneath it.
When did Albinism, Oculocutaneous trials start? (15)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2024 | 1 |
| 2020 | 1 |
| 2019 | 1 |
| 2018 | 1 |
| 2015 | 1 |
| 2014 | 1 |
| 2012 | 1 |
| 2011 | 1 |
| 2010 | 1 |
Showing 10 of 15 earlier years.
No forecast is made for this condition: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 18 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Albinism, Oculocutaneous trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 1 |
| Phase 2 | 4 |
| Not applicable | 1 |
| Observational | 11 |
How many Albinism, Oculocutaneous trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 3 |
| Active, not recruiting | 2 |
| Completed | 9 |
| Terminated | 2 |
| Withdrawn | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Albinism, Oculocutaneous trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Human Genome Research Institute (NHGRI) | 6 |
| 23andMe, Inc. | 1 |
| National Eye Institute (NEI) | 1 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 1 |
| William Gahl, M.D. | 1 |
Which drugs are being tested for Albinism, Oculocutaneous? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| INFLIXIMAB | 1 |
| MERCAPTOPURINE | 1 |
| Zileuton | 1 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Pirfenidoneone | 2 |
| Adalimumab-US | 1 |
| Pravastatin Pill | 1 |
| Low dose losartan | 1 |
| N Acetylcysteine | 1 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Albinism, Oculocutaneous trials report? (5)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Respiratory failure | 5 | 2 |
| Blood creatinine phosphokinase increased | 2 | 1 |
| Chest pain | 2 | 1 |
| Deep vein thrombosis | 1 | 1 |
| Haematochezia | 1 | 1 |
Which publications cover Albinism, Oculocutaneous? (10)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Microperimetric biofeedback in a patient with oculocutaneous albinism. | Canadian journal of ophthalmology. Journal canadien d'ophtalmologie | 2013 | Yes |
| Effects of extraocular muscle surgery on 15 patients with oculo-cutaneous albinism (OCA) and infantile nystagmus syndrome (INS). | American journal of ophthalmology | 2004 | Yes |
| Tyrosinase gene mutations in oculocutaneous albinism 1 (OCA1): definition of the phenotype. | Human genetics | 2003 | Yes |
| Genetic defects and clinical characteristics of patients with a form of oculocutaneous albinism (Hermansky-Pudlak syndrome). | The New England journal of medicine | 1998 | Yes |
| Evoked potential analysis of visual pathways in human albinism. | Ophthalmology | 1994 | Yes |
Showing 5 of 10 publications.
Prevalence (9)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Oculocutaneous albinism | Prevalence at birth | 1-9 / 100 000 | Denmark | Not stated | Unspecified |
| Oculocutaneous albinism | Point prevalence | 1-5 / 10 000 | South Africa | Not stated | Unspecified |
| Oculocutaneous albinism | Point prevalence | 1-9 / 100 000 | Worldwide | Not stated | Exact |
| Oculocutaneous albinism | Prevalence at birth | 1-9 / 100 000 | Denmark | Not stated | Exact |
| Oculocutaneous albinism | Prevalence at birth | 1-9 / 100 000 | Denmark | Not stated | Exact |
Showing 5 of 9 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Oculocutaneous albinism | 55 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Oculocutaneous albinism | 55 | Exact | Orphadata Science knowledge files, Product 1 |
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.